FrancophonIA/ELRC3.0 huggingface dataset:
English: Baseline characteristics were well balanced between the two treatment groups with respect to age (median age was 46 years for the SPRYCEL group and 49 years for the imatinib group with 10% and 11% of patients 65 years of age or older, respectively), gender (women 44% and 37%, respectively), and race (Caucasian 51% and 55%; Asian 42% and 37%, respectively).
Croatian: Bolesnici u dvije terapijske skupine bili su slični u osnovnim značajkama kao što su dob (medijan dobi iznosio je 46 godina u skupini koja je primala SPRYCEL, u kojoj je 10% bolesnika bilo u dobi od 65 ili više godina, te 49 godina u skupini koja je primala imatinib, u kojoj je 11% bolesnika bilo u dobi od 65 ili više godina), spol (44% žena u skupini koja je primala SPRYCEL i 37% u skupini koja je primala imatinib) i rasa (51% bijelaca i 42% azijata u skupini koja je primala SPRYCEL te 55% bijelaca i 37% azijata u skupini koja je primala imatinib).
English: In clinical studies, treatment with SPRYCEL in paediatric patients with Ph+ ALL was administered continuously, added to successive blocks of backbone chemotherapy, for a maximum duration of two years.
Croatian: U kliničkim se ispitivanjima SPRYCEL u pedijatrijskih bolesnika s Ph+ ALL primjenjivao kontinuirano, kao dodatak uzastopnim blokovima osnovne kemoterapije, tijekom najviše dvije godine.
English: There is limited experience with the use of SPRYCEL in this age group.
Croatian: Iskustvo s primjenom lijeka SPRYCEL u ovoj dobnoj skupini je ograničeno.
English: Rare diabetes mellitus
Croatian: Rijetko šećerna bolest
English: A total of 670 patients, of whom 497 were imatinib-resistant, were randomised to the dasatinib 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily group.
Croatian: Ukupno je bilo randomizirano 670 bolesnika, od kojih je 497 bilo otporno na imatinib, u četiri skupine koje su primale sljedeće doze dasatiniba: 100 mg jedanput dnevno, 140 mg jedanput dnevno, 50 mg dvaput dnevno ili 70 mg dvaput dnevno.
English: Discontinuation within 12 months due to disease progression occurred in 3% of SPRYCEL-treated patients and 5% of imatinib-treated patients.
Croatian: Prekid liječenja unutar 12 mjeseci zbog napredovanja bolesti dogodio se u 3% bolesnika liječenih lijekom SPRYCEL i 5% bolesnika liječenih imatinibom.
English: Carton containing one bottle with 60 film-coated tablets.
Croatian: Kutija sadrži jednu bocu sa 60 filmom obloženih tableta.
English: The cardiac adverse reactions of congestive heart failure/cardiac dysfunction, pericardial effusion, arrhythmias, palpitations, QT prolongation and myocardial infarction (including fatal) were reported in patients taking dasatinib.
Croatian: Srčane nuspojave kao što su kongestivno zatajivanje srca/srčana disfunkcija, perikardijalni izljev, aritmije, palpitacije, produljenje QT intervala i infarkt miokarda (uključujući slučajeve sa smrtnim ishodom) bile su zabilježene u bolesnika koji su uzimali dasatinib.
English: One bottle of powder for oral suspension contains 990 mg of dasatinib (as monohydrate).
Croatian: Jedna boca praška za oralnu suspenziju sadrži 990 mg dasatiniba (u obliku hidrata).
English: SPRYCEL is administered orally once daily in the form of either SPRYCEL tablets or SPRYCEL powder for oral suspension.
Croatian: SPRYCEL se primjenjuje jedanput dnevno kroz usta u obliku SPRYCEL tableta ili SPRYCEL praška za oralnu suspenziju.
English: Not known atrial fibrillation/atrial flutter Vascular disorders
Croatian: Nepoznato fibrilacija atrija/ undulacija atrija Krvožilni poremećaji
English: Common congestive heart failure/cardiac dysfunction*c, pericardial effusion*, arrhythmia (including tachycardia), palpitations
Croatian: Često kongestivno zatajenje srca/srčana disfunkcija*c, perikardijalni izljev*, aritmije (uključujući tahikardiju), palpitacije
English: How to take SPRYCEL
Croatian: Kako uzimati SPRYCEL
English: Table 5: Tabulated summary of adverse reactions
Croatian: Tablica 5: Tablični sažetak nuspojava
English: A PPK model-based simulation predicted that the body weight tiered dosing recommendation described for the tablet, in section 4.2, is expected to provide similar exposure to a tablet dose of 60 mg/m2.
Croatian: Prema simulaciji utemeljenoj na populacijskom farmakokinetičkom modelu, očekuje se da će preporučeno doziranje tableta prema kategorijama tjelesne težine navedeno u dijelu 4.2 dovesti do slične izloženosti kao tablete u dozi od 60 mg/m2.
English: Digestive problems: loss of vital nutrients such as protein from your digestive tract, bowel obstruction, anal fistula (an abnormal opening from the anus to the skin around the anus), impairment of kidney function, diabetes
Croatian: Probavni problemi: gubitak vitalnih hranjivih tvari kao što su proteini iz probavnog trakta, začepljenje crijeva, analna fistula (abnormalan otvor koji vodi od anusa do kože oko anusa), poremećaj funkcije bubrega, šećerna bolest
English: Other secondary endpoints included duration of MCyR, PFS, and overall survival.
Croatian: Drugi sekundarni ishodi bili su trajanje značajnog citogenetskog odgovora, PFS i ukupno preživljenje.
English: In the paediatric ALL studies, the rates of laboratory abnormalities were consistent with the known profile for laboratory parameters in adults, within the context of an acute leukaemia patient receiving a background chemotherapy regimen.
Croatian: U ispitivanjima liječenja ALL u pedijatrijskih bolesnika stope odstupanja u laboratorijskim nalazima odgovarale su poznatom profilu za laboratorijske parametre u odraslih, u kontekstu bolesnika s akutnom leukemijom liječenog osnovnim kemoterapijskim režimom.
English: Of the 126 Ph+ ALL paediatric patients on a continuous dosing regimen, 2 (1.6%) experienced adverse reactions leading to treatment discontinuation.
Croatian: Od 126 pedijatrijskih bolesnika s Ph+ ALL liječenih prema režimu kontinuirane primjene, 2 (1,6%) bolesnika imala su nuspojave koje su dovele do prekida liječenja.
English: Temporary dose reductions for intermediate degrees of cytopaenia and disease response should be implemented as needed.
Croatian: Po potrebi treba privremeno smanjiti dozu u slučaju citopenije srednjeg stupnja i odgovora bolesti.
English: In the newly diagnosed chronic phase CML study after a minimum of 60 months follow-up, dasatinib-related fluid retention adverse reactions included pleural effusion (28%), superficial oedema (14%), pulmonary hypertension (5%), generalised oedema (4%), and pericardial effusion (4%).
Croatian: Nakon najmanje 60 mjeseci praćenja u ispitivanju provedenom u bolesnika s novodijagnosticiranom KML u kroničnoj fazi, nuspojave zadržavanja tekućine uzrokovani primjenom dasatiniba uključivali su pleuralni izljev (28%), površinski edem (14%), plućnu hipertenziju (5%), generalizirani edem (4%) i perikardijalni izljev (4%).
English: Lymphoid toxicity in rats consisted of lymphoid depletion of the lymph nodes, spleen, and thymus, and decreased lymphoid organ weights.
Croatian: Limfoidna toksičnost u štakora sastojala se od limfoidne deplecije u limfnim čvorovima, slezeni i timusu, te smanjene težine limfnih organa.
English: What SPRYCEL contains The active substance is dasatinib.
Croatian: Što SPRYCEL sadrži Djelatna tvar je dasatinib.
English: For paediatric patients with Ph+ CML-CP, if Grade ≥3 neutropaenia or thrombocytopaenia recurs during complete haematologic response (CHR), SPRYCEL should be interrupted, and may be subsequently resumed at a reduced dose.
Croatian: Ako u pedijatrijskih bolesnika s Ph+ KML u kroničnoj fazi ponovno nastupe neutropenija ili trombocitopenija ≥ 3. stupnja tijekom potpunog hematološkog odgovora, primjenu lijeka SPRYCEL potrebno je privremeno prekinuti, a zatim nastaviti liječenje smanjenom dozom.
English: Data from healthy subjects administered a single 100 mg dose of dasatinib 30 minutes following a high-fat meal indicated a 14% increase in the mean AUC of dasatinib.
Croatian: Podaci prikupljeni u zdravih ispitanika koji su primili pojedinačnu dozu dasatiniba od 100 mg 30 minuta nakon obroka bogatog masnoćama ukazuju na 14%-tno povećanje prosječne AUC dasatiniba.
English: The recommended starting dose for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ ALL is 140 mg once daily (see section 4.4).
Croatian: Preporučena početna doza dasatiniba u fazi ubrzanja, fazi mijeloidne ili limfoidne blastne krize (uznapredovala faza) KML ili Ph+ ALL iznosi 140 mg jedanput dnevno (vidjeti dio 4.4).
English: Tests may show: fluid around the heart, fluid in the lungs, arrhythmia, febrile neutropaenia, gastrointestinal bleeding, high uric acid levels in the blood
Croatian: Pretrage mogu pokazati: tekućina oko srca, tekućina u plućima, aritmija (poremećaj srčanog ritma), febrilna neutropenija, krvarenje u probavni sustav, velika koncentracija mokraćne kiseline u krvi
English: The other ingredients are: sucrose, carmellose sodium, simethicone emulsion (consisting of simeticone, polyethylene glycol sorbitan tristearate, polyethoxylate stearate, glycerides, methylcellulose, xanthan gum, benzoic acid, sorbic acid, sulfuric acid), tartaric acid, trisodium citrate anhydrous, sodium benzoate (E211), silica hydrophobic colloidal, mixed berry flavour (containing: benzyl alcohol, sulphur dioxide) (see section 2 "What you need to know before you take SPRYCEL").
Croatian: Drugi sastojci su: saharoza, karmelozanatrij, simetikon emulzija (sastoji se od simetikona, polietilenglikolsorbitantristearata, polietoksilatstearata, glicerida, metilceluloze, ksantanske gume, benzoatne kiseline, sorbatne kiseline i sumporne kiseline), tartaratna kiselina, bezvodni trinatrijev citrat, natrijev benzoat (E211), hidrofobni koloidni silicijev dioksid, aroma miješanog bobičastog voća (koja sadrži benzilni alkohol i sumporov dioksid) (vidjeti dio 2."Što morate znati prije nego počnete uzimati SPRYCEL").
English: Treatment with dasatinib is associated with anaemia, neutropaenia and thrombocytopaenia.
Croatian: Liječenje dasatinibom povezano je s anemijom, neutropenijom i trombocitopenijom.
English: c Cytogenetic response criteria: complete (0% Ph+ metaphases) or partial (>0%-35%).
Croatian: c Kriteriji citogenetskog odgovora: potpuni (0% Ph+ metafaze) ili djelomični (> 0%-35%).
English: Constituted oral suspension may be further mixed with milk, yogurt, apple juice, or applesauce.
Croatian: Rekonstituirana oralna suspenzija može se dodatno pomiješati s mlijekom, jogurtom ili bistrim/gustim sokom od jabuke.
English: Unopened bottle 2 years.
Croatian: Neotvorena boca
English: An open-label, randomised, non-comparative multicentre study was conducted in patients who failed initial treatment with 400 or 600 mg imatinib.
Croatian: Randomizirano, multicentrično, nekomparativno ispitivanje otvorenog tipa provelo se u bolesnika u kojih početno liječenje imatinibom u dozi od 400 ili 600 mg nije bilo uspješno.
English: ANC < 0.5 x 109/L and/or platelets < 10 x 109/L
Croatian: ABN <0,5×109/l i/ili trombociti <10×109/l
English: Second dose (mL)
Croatian: Druga doza (ml)
English: SPRYCEL should not be taken with grapefruit or grapefruit juice (see section 4.5).
Croatian: SPRYCEL se ne smije uzimati s grejpom ni sokom od grejpa (vidjeti dio 4.5).
English: A statistically significantly greater proportion of patients in the SPRYCEL group achieved a cCCyR compared with patients in the imatinib group within the first 12 months of treatment.
Croatian: Udio bolesnika koji su postigli cCCyR bio je statistički značajno veći u skupini koja je primala SPRYCEL nego u skupini koja je primala imatinib u prvih 12 mjeseci liječenja.
English: In the Phase II paediatric study, 1 newly diagnosed patient and 2 imatinib-resistant or intolerant patients progressed to blast phase CML.
Croatian: U pedijatrijskom ispitivanju faze II, u 1 bolesnika s novodijagnosticiranom bolešću i 2 bolesnika koja su bila otporna na imatinib ili ga nisu podnosila došlo je do progresije KML do faze blastne krize.
English: Your doctor will decide the right dose based on your weight.
Croatian: Liječnik će odrediti pravu dozu za Vas na temelju
English: Patients with BCR-ABL > 10% at 3 months
Croatian: Bolesnici koji su imali BCR-ABL > 10% u 3. mjesecu
English: In addition, one open-label, randomised, comparative Phase III study was conducted in adult patients with newly diagnosed chronic phase CML.
Croatian: Uz to je provedeno i jedno otvoreno, randomizirano, komparativno ispitivanje faze III u odraslih bolesnika s novodijagnosticiranom KML u kroničnoj fazi.
English: Long-term suppression of gastric acid secretion by H2 antagonists or proton pump inhibitors (e.g. famotidine and omeprazole) is likely to reduce dasatinib exposure.
Croatian: Dugotrajna supresija sekrecije želučane kiseline antagonistima H2 receptora ili inhibitorima protonske pumpe (npr. famotidin ili omeprazol) vjerojatno će smanjiti izloženost dasatinibu.
English: No clinically relevant age-related pharmacokinetic differences have been observed in these patients.
Croatian: U starijih bolesnika nisu primijećene klinički važne razlike u farmakokinetici povezane s dobi.
English: Myeloid blast phase (n= 74)c
Croatian: Mijeloidna blastna kriza (n= 74)c
English: Grade 3 or 4 elevations in creatinine were reported in < 1% of patients with chronic phase CML and were reported with an increased frequency of 1 to 4% of patients with advanced phase CML.
Croatian: Povišenje kreatinina 3. ili 4. stupnja bilo je prijavljeno u <1% bolesnika s KML u kroničnoj fazi te uz povećanu učestalost od 1 do 4% u bolesnika u uznapredovaloj fazi KML.
English: Table 14: Efficacy of SPRYCEL in phase III dose-optimisation study: advanced phase CML and Ph+ ALL (2 year results)a
Croatian: Tablica 14: Djelotvornost lijeka SPRYCEL u ispitivanju optimizacije doze faze III: uznapredovala faza KML i Ph+ ALL (2-godišnji rezultati)a
English: The dose for the use of powder for oral suspension in adult patients with accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ ALL has not been determined.
Croatian: Doza praška za oralnu suspenziju za primjenu u odraslih bolesnika u fazi ubrzanja ili fazi mijeloidne ili limfoidne blastne krize (uznapredovala faza) KML ili Ph+ ALL nije utvrđena.
English: At clinically relevant concentrations, binding of dasatinib to plasma proteins is approximately 96% on the basis of in vitro experiments.
Croatian: Na temelju ispitivanja in vitro, vezanje dasatiniba za proteine plazme pri klinički značajnim koncentracijama iznosi oko 96%.
English: The mean Cmax and AUC of dasatinib adjusted for the 70 mg dose were decreased by 47% and 8%, respectively, in subjects with moderate hepatic impairment compared to subjects with normal hepatic function.
Croatian: Srednja vrijednost Cmax i AUC dasatiniba prilagođenu za dozu od 70 mg bila je smanjena za 47% kod bolesnika sa umjerenim oštećenjem jetre u odnosu na 8% kod bolesnika sa normalnom jetrenom funkcijom.
English: The median time from diagnosis to randomisation was 64 months in the dasatinib group and 52 months in the imatinib group.
Croatian: Medijan vremena od dijagnoze do randomizacije iznosio je 64 mjeseca u skupini koja je primala dasatinib te 52 mjeseca u skupini koja je primala imatinib.
English: Approximately 5% of the SPRYCEL-treated patients who had normal baseline levels experienced grade 3 or 4 transient hypocalcaemia at some time during the course of the study.
Croatian: U oko 5% bolesnika liječenih lijekom SPRYCEL, koji su imali normalne početne vrijednosti kalcija, u nekom je trenutku tijekom trajanja ispitivanja nastupila prolazna hipokalcijemija 3. ili 4. stupnja.
English: SPRYCEL contains 0.017 mg benzyl alcohol in each mL of oral suspension.
Croatian: SPRYCEL sadrži 0,017 mg benzilnog alkohola u jednom ml oralne suspenzije.
English: All patients Imatinib-resistant patients a Results reported in recommended starting dose of 100 mg once daily.
Croatian: Svi bolesnici Bolesnici otporni na imatinib a Rezultati prijavljeni uz primjenu preporučene početne doze od 100 mg jedanput dnevno.
English: This medicine is used to treat chronic myeloid leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in adolescents and children from at least one year of age.
Croatian: Ovaj se lijek koristi za liječenje kronične mijeloične leukemije (KML) te akutne limfoblastične leukemije (ALL) s pozitivnim Philadelphia kromosomom (Ph+) u adolescenata i djece u dobi od najmanje godinu dana.
English: PROPORTION RESPONDERS
Croatian: Način primjene
English: Thus, H2 antagonists and proton pump inhibitors are not recommended and aluminium hydroxide/magnesium hydroxide products should be administered up to 2 hours prior to, or 2 hours following the administration of dasatinib (see section 4.5).
Croatian: Zbog toga se ne preporučuje istodobna primjena antagonista H2 receptora i inhibitora protonske pumpe, dok se pripravci s aluminijevim hidroksidom ili magnezijevim hidroksidom moraju primijeniti najmanje 2 sata prije ili 2 sata poslije primjene dasatiniba (vidjeti dio 4.5).
English: The tablet is not recommended for patients weighing less than 10 kg; the powder for oral suspension should be used for these patients.
Croatian: Tableta se ne preporučuje za bolesnike koji teže manje od 10 kg; u tih bolesnika treba koristiti prašak za oralnu suspenziju.
English: The majority of SPRYCEL-treated patients experienced adverse reactions at some time.
Croatian: Većina bolesnika koji su primali SPRYCEL u nekom je trenutku tijekom liječenja razvila nuspojave.
English: SPRYCEL 20 mg, SPRYCEL 50 mg and SPRYCEL 70 mg film-coated tablets Alu/Alu blisters (calendar blisters or perforated unit dose blisters).
Croatian: SPRYCEL 20 mg, SPRYCEL 50 mg i SPRYCEL 70 mg filmom obložene tablete Alu/Alu blisteri (kalendarski blisteri ili perforirani blisteri djeljivi na jedinične doze).
English: ANC < 0.5 x 109/L and/or platelets < 50 x 109/L
Croatian: ABN <0,5×109/l i/ili trombociti <50×109/l
English: In the Phase I paediatric study, after a minimum of 7 years of follow-up among the 17 patients with imatinib-resistant or intolerant CML-CP, the median duration of PFS was 53.6 months and the rate of OS was 82.4%.
Croatian: Nakon minimalno 7 godina praćenja u pedijatrijskom ispitivanju faze I, medijan trajanja PFS među 17 bolesnika s KML u kroničnoj fazi koji su bili otporni na imatinib ili ga nisu podnosili iznosio je 53,6 mjeseci, dok je stopa OS iznosila 82,4%.
English: If you have any questions about how SPRYCEL works or why this medicine has been prescribed for you, ask your doctor.
Croatian: Ako imate dodatnih pitanja o načinu djelovanja lijeka SPRYCEL ili razlogu zašto Vam je propisan ovaj lijek, obratite se liječniku.
English: Patients aged 65 years and older are more likely than younger patients to experience pleural effusion, dyspnoea, cough, pericardial effusion and congestive heart failure, and should be monitored closely.
Croatian: U bolesnika u dobi od 65 ili više godina veća je vjerojatnost pleuralnog izljeva, dispneje, kašlja, perikardijalnog izljeva i kongestivnog zatajenja srca nego u mlađih bolesnika, pa stoga stariji bolesnici moraju biti strogo nadzirani.
English: There is insufficient/limited information on the excretion of dasatinib in human or animal breast milk.
Croatian: Informacije o izlučivanju dasatiniba u majčino mlijeko u ljudi ili životinja nedostatne su ili ograničene.
English: If marrow cellularity is <10%, treatment with SPRYCEL should be interrupted until ANC >500/μL (0.5 x 109/L), at which time treatment may be resumed at full dose.
Croatian: Ako je celularnost koštane srži < 10%, liječenje lijekom SPRYCEL potrebno je privremeno prekinuti dok ABN ne bude > 500//μl (0,5 x 109/l), kada se liječenje može nastaviti punom dozom.
English: Lymphoid blast phase CML and Ph+ ALL
Croatian: Limfoidna blastna kriza KML i Ph+ ALL
English: SPRYCEL is also used to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in adults, adolescents and children at least 1 year of age, and lymphoid blast CML in adults who are not benefiting from prior therapies.
Croatian: SPRYCEL se koristi i za liječenje akutne limfoblastične leukemije (ALL) s pozitivnim Philadelphia kromosomom (Ph+) u odraslih, adolescenata i djece u dobi od najmanje godinu dana te limfoidne blastne KML u odraslih u kojih prethodno liječenje nije dovelo do poboljšanja.
English: Advise patients who are or may become pregnant of the potential risk to the foetus from dasatinib and the excipient benzyl alcohol, which may accumulate over time and cause metabolic acidosis.
Croatian: Trudnice i bolesnice koje bi mogle zatrudnjeti treba upozoriti na mogući rizik za dijete povezan s dasatinibom i pomoćnom tvari benzilnim alkoholom, koji se s vremenom može nakupljati i uzrokovati metaboličku acidozu.
English: If a severe grade 3 or 4, non-haematologic adverse reaction develops with dasatinib, treatment must be withheld until the adverse reaction has resolved.
Croatian: Ako se uz liječenje dasatinibom razvije teška nehematološka nuspojava 3. ili 4. stupnja, liječenje se mora obustaviti sve dok se nuspojava ne povuče.
English: Chronic phase CML - Resistance or intolerance to prior imatinib therapy
Croatian: Kronična faza KML - nepodnošenje prethodne terapije imatinibom ili otpornost na imatinib
English: 120-mL high-density polyethylene bottle with polypropylene child-resistant closure containing 33 g of powder for oral suspension.
Croatian: Boca od polietilena visoke gustoće volumena 120 ml s polipropilenskim zatvaračem sigurnim za djecu koja sadrži 33 g praška za oralnu suspenziju.
English: Uncommon hepatitis, cholecystitis, cholestasis Skin and subcutaneous tissue disorders
Croatian: Manje često hepatitis, kolecistitis, kolestaza Poremećaji kože i potkožnog tkiva
English: For patients taking SPRYCEL 60 mg or 40 mg daily, consider interrupting the dose of SPRYCEL until the CYP3A4 inhibitor is discontinued, or switching to a lower dose with the powder for oral suspension formulation (see Summary of Product Characteristics for SPRYCEL powder for oral suspension).
Croatian: U bolesnika koji uzimaju SPRYCEL u dozi od 60 mg ili 40 mg dnevno potrebno je razmotriti privremeni prekid primjene lijeka SPRYCEL do prestanka liječenja inhibitorom CYP3A4 ili prelazak na nižu dozu primjenom praška za oralnu suspenziju (vidjeti sažetak opisa svojstava lijeka za SPRYCEL prašak za oralnu suspenziju).
English: Adults with accelerated and blast phase CML and Ph+ ALL (starting dose 140 mg once daily)
Croatian: Odrasli u fazi ubrzanja i blastnoj fazi KML i Ph+ ALL (početna doza od 140 mg jedanput dnevno)
English: A PPK model-based simulation predicted that the body weight tiered dosing recommendation described for the powder for oral suspension, in section 4.2 of the Summary of Product Characteristics for the powder for oral suspension, is expected to provide similar exposure to a tablet dose of 60 mg/m2.
Croatian: Prema simulaciji utemeljenoj na populacijskom farmakokinetičkom modelu, očekuje se da će preporučeno doziranje praška za oralnu suspenziju prema kategorijama tjelesne težine, navedeno u dijelu 4.2 sažetka opisa svojstava lijeka za tu formulaciju dovesti do slične izloženosti kao tablete u dozi od 60 mg/m2.
English: The concomitant use of dasatinib and a histamine-2 (H2) antagonist (e.g. famotidine), proton pump inhibitor (e.g. omeprazole), or aluminium hydroxide/magnesium hydroxide may reduce the exposure to dasatinib.
Croatian: Istodobna primjena dasatiniba i antagonista histaminskih H2 receptora (npr. famotidin), inhibitora protonske pumpe (npr. omeprazol) ili aluminijevog hidroksida/magnezijevog hidroksida može smanjiti izloženost dasatinibu.
English: Grade 3 or 4 elevations of transaminases or bilirubin were reported in 1% of patients with chronic phase CML (resistant or intolerant to imatinib), but elevations were reported with an increased frequency of 1 to 7% of patients with advanced phase CML and Ph+ ALL.
Croatian: Povišenje 3. ili 4. stupnja u vrijednostima transaminaza ili bilirubina bilo je prijavljeno u 1% bolesnika s KML u kroničnoj fazi (koji ne podnose prethodnu terapiju imatinibom ili su otporni na imatinib) te uz zabilježeno povišenu učestalost od 1 do 7% u bolesnika u uznapredovaloj fazi KML i Ph+ ALL.